超50只基金翻倍！这两大赛道成最大赢家

Core Insights - The performance of public funds in the first three quarters of 2025 shows significant differentiation, with over 50 funds doubling their net value, particularly in technology and pharmaceutical themes, while funds heavily invested in traditional finance and cyclical sectors performed poorly [1][2]. Fund Performance - Active equity funds achieved an average return of 34.54% year-to-date, outperforming passive index funds which averaged 27.56% [2]. - A total of 53 funds recorded returns exceeding 100%, with 48 being active equity funds, highlighting the success of active management in a structural market [2]. - The top-performing fund, Yongying Technology Smart A, had a return of 194.49%, followed by Huatai-PB Hong Kong Advantage Selection A at 161.1%, both focusing on technology and innovative pharmaceuticals [2]. Traditional Sector Performance - In contrast, 41 funds reported returns below -5%, with 27 being active equity funds, primarily invested in traditional sectors like banking, real estate, and consumer goods [3]. - The performance gap between the best and worst active equity funds exceeded 200 percentage points, indicating a high level of market differentiation [3]. Gold ETFs - Gold ETFs have seen significant inflows due to their strong safe-haven appeal, with an average return of 41.04% year-to-date, outperforming the broader market [4]. - All 14 gold ETFs recorded positive growth in shares, with the largest ETF increasing by over 3.3 billion shares, and total market shares surpassing 20 billion [4]. Market Outlook - The market is expected to continue its differentiation, with technology and innovative pharmaceuticals likely to remain the main themes in Q4 [5][6]. - Investment strategies should focus on "high-cut low" approaches, shifting from high-performing sectors to undervalued areas [6][7]. - The innovation drug sector may see reduced overall beta in Q4, suggesting a focus on individual stock opportunities rather than broad sector plays [7].